Trevena, Inc. Overview
Pro stress-test →Trevena is a clinical-stage biopharmaceutical company focused on developing innovative medicines for central nervous system disorders using biased ligand technology. The company's FDA-approved lead product OLINVYK (oliceridine) targets acute pain management, with a pipeline addressing conditions including migraine, opioid use disorder, and neuropathic pain.
Strategic Profile
Pro stress-test →Trevena leverages proprietary G-protein coupled receptor (GPCR) biased ligand technology licensed from Duke University to create drugs with improved efficacy and reduced side effects. The company operates as a virtual organization with approximately 23 employees, focusing on commercial execution of OLINVYK while advancing pipeline candidates through collaboration with academic institutions and the NIH.
Competitive Landscape
Pro stress-test →Trevena competes in the biopharmaceutical space against NGM Biopharmaceuticals, Array BioPharma, and Threshold Pharmaceuticals, as well as broader pain management competitors including traditional opioid manufacturers. Trevena's competitive advantage lies in its biased ligand approach, which targets reduced side effects compared to conventional therapies, but faces headwinds from opioid stigma and regulatory scrutiny.
Industry Context
Trevena, Inc. operates in Biopharmaceuticals - CNS Disorders.
Key facts
Founded: 2007 · Headquarters: Chesterbrook, Pennsylvania · Employees: 23 · Revenue: $3.1M (2022) · Market cap: $1.03M